Extended Data Fig. 1: Study schema of: A, overview of study design, and B, overview of response assessments. | Nature Medicine

Extended Data Fig. 1: Study schema of: A, overview of study design, and B, overview of response assessments.

From: Mosunetuzumab with polatuzumab vedotin in relapsed or refractory aggressive large B cell lymphoma: a phase 1b/2 trial

Extended Data Fig. 1

aSafety data of the first 6 safety-evaluable patients enrolled in Arm K will be reviewed by the IMC prior to enrolling the full expansion cohort; bSee protocol section 3.1.5 for mosun treatment beyond 8 cycles and re-treatment; cSee protocol section 3.1.5 for mosun re-treatment; dSee protocol section 3.1.5 for Arm M-crossover. 2 L, second line; C, cycle; CT, computerised tomography; FL, follicular lymphoma; DLBCL, diffuse large B-cell lymphoma; IMC, internal monitoring committee; IV, intravenous; MCL, mantle cell lymphoma; Mosun, mosunetuzumab; N, number; PET, positron emission tomography; Pola, polatuzumab vedotin; PR, partial response; R/R, relapsed/refractory; SC, subcutaneous; SD, stable disease.

Back to article page